MaxCyte IPO Presentation Deck

Building a Large Portfolio of Diverse Customers MaxCyte's customer base reflects the industry in diversity of cell types, sources, and indications Cell Type/Approach Cell Therapy, Market July 2021 CAR-T Stem Cell MaxCyte Partners TCR Other CAR-NK/NK Cell Therapy Market Cell Source Auto MaxCyte Partners Allo Cell Therapy, Market CONFIDENTIAL MM Note: * All clinical gene modified cell therapies across therapeutic areas (e.g., ancology, inherited disorders, immune disorders) utilizing viral and/or non-viral delivery are included, while other regenerative medicine programs that do not entail genetic modification to obtain a cell-based therapeutic product (e.g.. tissue engineering, immune or stem cell therapies that are not genetically modified) are excluded. Pancreatic Other Solid Tumors Indications MaxCyte Partners AML / ALL Lung Genetic Disorders Other Heme Malig Ovarian NHL Other M MaxCyte

View entire presentation